| Literature DB >> 34255048 |
Tatum M Cummins1,2, Oliver English3, Helen Minnis4, Daniel Stahl5, Rory C O'Connor6, Kirsty Bannister2, Stephen B McMahon1, Dennis Ougrin3.
Abstract
Importance: Self-harm is a risk factor for suicide in adolescents, with the prevalence highest in young people in group and residential care programs. Although no established risk factors for self-harm exist, adolescents who self-harm may have decreased pain sensitivity, but this has not been systematically investigated. Objective: To assess somatosensory function using quantitative sensory testing (QST) in children and adolescents living in care grouped by the number of episodes of self-harm in the past year and compare their somatosensory profiles with community control participants to investigate associations with the incidence or frequency of self-harm. Design, Setting, and Participants: Recruitment for this cross-sectional study began January 2019 and ended March 2020. Exclusion criteria included intellectual disability (intelligence quotient <70), autism spectrum disorder, or recent serious injury. Children and adolescents aged 12 to 17 years with no underlying health conditions were recruited from local authority residential care settings in Glasgow, UK, and schools and youth groups in London and Glasgow, UK. The volunteer sample of 64 participants included adolescents ages 13 to 17 years (34 [53%] females; 50 [78%] living in residential care; mean [SD] age, 16.34 [1.01] years) with varying incidents of self-harm in the past year (no episodes, 31 [48%]; 1-4 episodes, 12 [19%]; and ≥5 episodes, 2 [33%]). Exposures: Participants were tested using a standardized QST protocol to establish baseline somatosensory function. Main Outcomes and Measures: Associations between somatosensory sensitivity, incidence and frequency of self-harm, residential status, age, gender, and prescription medication were calculated. Secondary outcomes assessed whether self-harm was associated with specific types of tests (ie, painful or nonpainful).Entities:
Mesh:
Year: 2021 PMID: 34255048 PMCID: PMC8278268 DOI: 10.1001/jamanetworkopen.2021.16853
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Participant Characteristics (N = 64)
| Characteristic | No. (%) | |||
|---|---|---|---|---|
| Control | No SH | SH 1-4 | SH ≥5 | |
| No. | 14 | 17 | 12 | 21 |
| Age, mean (SD), y | 16.4 (0.67) | 16.5 (1.02) | 16.2 (1.39) | 16.3 (0.99) |
| Gender | ||||
| Male | 2 (14.3) | 16 (94.1) | 8 (66.7) | 4 (19) |
| Female | 12 (85.7) | 1 (5.9) | 4 (33.3) | 17 (81) |
| Ethnicity | ||||
| White British | 11 (78.6) | 15 (88.2) | 11 (91.7) | 18 (85.7) |
| Ethnic minority | 3 (21.4) | 2 (11.8) | 1 (8.3) | 3 (14.3) |
| Medication | ||||
| None | 12 (85.7) | 14 (82.4) | 5 (41.7) | 8 (38.1) |
| Antidepressant | 2 (14.2) | 1 (5.9) | 4 (33.3) | 3 (14.3) |
| Antipsychotic | 1 (7.1) | 2 (11.8) | 1 (8.3) | 2 (9.5) |
| Other | 0 | 3 (17.7) | 5 (41.7) | 13 (61.9) |
| Diagnosis | ||||
| None | 14 (100) | 6 (35.3) | 1 (8.3) | 1 (4.8) |
| Internalizing | 0 | 4 (23.5) | 5 41.7) | 18 (85.7) |
| Externalizing | 0 | 8 (47.1) | 5 (41.7) | 0 |
| Neurodevelopmental | 0 | 1 (5.9) | 3 (25) | 4 (19.1) |
| BPD threshold | 0 | 1 (5.9) | 7 (58.3) | 14 (66.7) |
| Mean (SD) | 3 (2.22) | 3.06 (2.28) | 6.64 (2.25) | 6.76 (2.63) |
| Suicidal thinking prior 6 mos | 3 (21.4) | 0 (0) | 2 (16.7) | 12 (57.1) |
Abbreviations: BPD, borderline personality disorder; SH, episodes of self-harm within the previous year.
Community control group included 3 participants with history of self-harm but not within previous year.
Ethnic minority describes individuals self-identifying as any ethnic group except the White British group.
Diagnosis included internalizing (ie, anxiety, depression, and mood disorders); externalizing (ie, conduct and substance disorders); neurodevelopmental (ie, attention deficit hyperactivity disorder).
BPD threshold was collected using the McLean Screening Instrument. The range of possible scores is 0-10; scores greater than or equal to 7 meet criteria for BPD.
Figure 1. Quantitative Sensory Testing (QST) z Scores for Unadjusted Pain Parameters
Each parameter shows significant variation by group and a similar trend to the group mean (SEM) pain scores, with the most frequent self-harm group showing significant hyposensitivity. Results outside of the SD of 1.96 (dotted line) indicate potentially abnormal thresholds. CPT indicates cold pain threshold; HPT, heat pain threshold; MPT, mechanical pain threshold; MPS, mechanical pain sensitivity; PPT, pressure pain threshold; SH, episodes of self-harm within the previous year; SH 1-4, 1 to 4 self-harm episodes within the previous year; SH ≥5, 5 or more self-harm episodes within the previous year.
aP < .05.
bP < .001.
cP < .01.
Pairwise Group Comparisons for Mean Pain Score (95% CI) Unadjusted and Adjusted for Age, Gender, and Prescription Drug Use
| Pairwise comparison | Mean difference (95% CI) | ||
|---|---|---|---|
| Group only | <.001 | ||
| No SH vs control | −0.28 (−0.74 to 0.18) | −1.22 | .23 |
| SH 1-4 vs control | −0.44 (−0.94 to 0.06) | −1.78 | .08 |
| SH ≥5 vs control | −1.01 (−1.45 to −0.57) | −4.60 | <.001 |
| SH 1-4 vs no SH | −0.17 (−0.64 to 0.31) | −0.69 | .49 |
| SH ≥5 vs no SH | −0.73 (−1.14 to −0.31) | −3.52 | .001 |
| SH ≥5 vs SH 1-4 | −0.56 (−1.02 to −0.11) | −2.46 | .02 |
| Adjusted for age, gender and prescription drug use | <.001 | ||
| No SH vs control | −0.57 (−1.14 to 0.002) | −1.99 | .05 |
| SH 1-4 vs control | −0.65 (−1.19 to −0.1) | −2.37 | .02 |
| SH ≥5 vs control | −1.03 (−1.47 to −0.60) | −4.75 | <.001 |
| SH 1-4 vs no SH | −0.08 (−0.57 to 0.41) | −0.32 | .75 |
| SH ≥5 vs no SH | −0.47 (−0.99 to 0.06) | −1.78 | .08 |
| SH ≥5 vs SH 1-4 | −0.39 (−0.89 to 0.11) | −1.55 | .13 |
Abbreviations: R2, variance; SH, episodes of self-harm within the previous year.
Figure 2. Quantitative Sensory Testing (QST) z Scores for Sensory (Nonpain) Parameters (Unadjusted)
The SH ≥5 group show significant hyposensitivity to sensory stimuli in general, and the young people in residential care with no SH show significant variation in thermal sensitivity compared with community control participants. Results outside of the SD of 1.96 (dotted line) indicate potentially abnormal thresholds. CDT indicates cold detection threshold; WDT, warm detection threshold; TSL, thermal sensory limen; MDT, mechanical detection threshold; SH, episodes of self-harm within the previous year; SH 1-4, 1 to 4 self-harm episodes within the previous year; SH ≥5, 5 or more self-harm episodes within the previous year; VDT, vibration detection threshold.
aP < .05.
bP < .001.
Pairwise Group Comparisons for Mean Sensory Score (95% CI) Unadjusted and Adjusted for Age, Gender, and Prescription Drug Use
| Pairwise comparison | Mean difference (95% CI) | ||
|---|---|---|---|
| Group only | .002 | ||
| No SH vs control | −1.09 (−2.01 to −0.18) | −2.4 | .02 |
| SH 1-4 vs control | −0.99 (−1.98 to 0.003) | −2 | .05 |
| SH ≥5 vs control | −1.75 (−2.62 to −0.88) | −4.02 | <.001 |
| SH 1-4 vs no SH | 0.10 (−0.85 to 1.06) | 0.22 | .83 |
| SH ≥5 vs no SH | −0.66 (−1.48 to 0.17) | −1.6 | .12 |
| SH ≥5 vs SH 1-4 | −0.76 (−1.67 to 0.15) | −1.66 | .10 |
| Adjusted for age, gender, and antidepressant | .003 | ||
| No SH vs control | −0.913 (−2.07 to 0.25) | −1.58 | .12 |
| SH 1-4 vs control | −0.86 (−1.96 to 0.25) | −1.54 | .13 |
| SH ≥5 vs control | −1.73 (−2.62 to −0.84) | −3.91 | <.001 |
| SH 1-4 vs no SH | 0.06 (−0.94 to 1.06) | 0.12 | .91 |
| SH ≥5 vs no SH | −0.82 (−1.88 to 0.25) | −1.54 | .13 |
| SH ≥5 vs SH 1-4 | −0.88 (−1.89 to 0.14) | −1.72 | .09 |
Abbreviation: SH, episodes of self-harm within the previous year.